CompletedPhase 1NCT00439010

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Molecular NeuroImaging
Principal Investigator
Danna Jennings, MD
Molecular NeuroImaging, LLC
Intervention
[123I] AV 39(drug)
Enrollment
30 enrolled
Eligibility
50 years · All sexes
Timeline
2007 – 2008

Study locations (1)

Collaborators

Institute for Neurodegenerative Disorders

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00439010 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials